Univo IRB announced the launch of its Canadian research ethics board (REB) review services. This new offering is designed to support clinical trials conducted across North America, ensuring that reviews exceed the industry’s highest standards of ethical integrity and regulatory compliance.
The introduction of Canadian ethical review services marks a significant expansion of Univo IRB’s capabilities. This initiative will provide researchers and sponsors with a streamlined process for obtaining Canadian REB approval, facilitating smoother and more efficient clinical trials.
“Under the guidance of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, this diverse group brings together experts in ethics, law, and scientific disciplines, alongside respected community ambassadors,” said Cyrus Gill, Executive Chair, Univo IRB. “By assembling this distinguished board for Canada and adhering to both Canadian and international regulatory requirements, we reaffirm our dedication to advancing research outside the U.S. responsibly and ethically, while unifying clinical research with our passion for patient protection, education, and advocacy.”
Univo IRB’s Canadian REB review services offer a comprehensive suite of support, including expedited review time lines, detailed feedback, and ongoing oversight throughout the trial life cycle. This proactive approach is designed to minimize delays and ensure that trials can proceed efficiently without compromising ethical standards.